Loading...
XNAS
KPTI
Market cap231mUSD
Jul 09, Last price  
10.20USD
1D
-4.40%
1Q
27.50%
Jan 2017
8.51%
IPO
-36.17%
Name

Karyopharm Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:KPTI chart
P/E
—
P/S
1.58
EPS
—
Div Yield, %
—
Shrs. gr., 5y
17.89%
Rev. gr., 5y
6.21%
Revenues
146m
+0.57%
152,000634,000387,000229,000250,000154,0001,605,00030,336,00040,893,000108,085,000209,819,000157,074,000146,033,000145,237,000146,067,000
Net income
-196m
L+156.52%
-10,311,000-15,888,000-33,947,000-75,777,000-118,181,000-109,577,000-128,984,000-178,407,000-199,590,000-196,273,000-124,088,000-165,291,000-143,099,000-76,422,000-196,039,000
CFO
-75m
L-40.88%
-8,549,000-15,509,000-30,290,000-51,447,000-94,029,000-84,391,000-73,717,000-159,117,000-190,822,000-160,234,000-107,116,000-149,554,000-92,723,000-127,486,000-75,369,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
URL
https://karyopharm.com/
IPO date
Nov 06, 2013
Employees
385
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT